Benzinga | Nov 17, 2021 07:41AM EST

Northland Capital Markets Downgrades Adamas Pharmaceuticals to Market Perform, Announces $8.5 Price Target

Northland Capital Markets analyst Carl Byrnes downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Outperform to Market Perform and announces $8.5 price target.